Skip to Main Content

Anticoagulation for Stroke Prevention and Recovery After ICH (ASPIRE

Conditions

Diseases of the Cardiovascular System | Diseases of the Nervous System

Phase III

What is the purpose of this trial?

Brief Summary:

Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF).

Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.

  • Trial with
    University of Cincinnati
  • Start Date
    02/27/2020
  • End Date
    04/29/2024
Trial Image

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/23/2020
  • Study HIC
    #2000026409